A phase II study of NK105 for patients with previously treated advanced or recurrent gastric cancer.
Phase 2
- Conditions
- Gastric cancer
- Registration Number
- JPRN-jRCT2080220741
- Lead Sponsor
- ippon Kayaku Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
1. Gastric cancer confirmed by histological diagnosis or cytologic diagnosis
2. Failure to one prior chemotherapy regimen for gastric cancer
3. Adequate organ function, etc
Exclusion Criteria
Priory treatments should not have included taxanes. etc
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Response propotion
- Secondary Outcome Measures
Name Time Method Adverse events<br>Time to treatment failure<br>Progression-free survival<br>Overall survival
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie NK105's anti-tumor activity in gastric cancer?
How does NK105 compare to fluoropyrimidine-based chemotherapy in advanced gastric cancer?
Which biomarkers correlate with clinical response to NK105 in recurrent gastric cancer?
What are the safety profiles and management strategies for NK105-related adverse events?
What NK cell-based therapies are in development for gastric cancer alongside Ippon Kayaku's pipeline?